Genus (GNS) Competitors

Genus (LON:GNS) and Dechra Pharmaceuticals (LON:DPH) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, earnings, profitability, analyst recommendations, dividends, valuation, risk and community ranking.

Does the MarketBeat Community believe in GNS or DPH?

Genus received 8 more outperform votes than Dechra Pharmaceuticals when rated by MarketBeat users. Likewise, 70.54% of users gave Genus an outperform vote while only 63.00% of users gave Dechra Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Genus	Outperform Votes 352 70.54%	Underperform Votes 147 29.46%
Dechra Pharmaceuticals	Outperform Votes 344 63.00%	Underperform Votes 202 37.00%

Which has preferable valuation and earnings, GNS or DPH?

Genus has higher earnings, but lower revenue than Dechra Pharmaceuticals. Dechra Pharmaceuticals is trading at a lower price-to-earnings ratio than Genus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genus	£666.67M	1.86	£7.87M	£12.06	156.66
Dechra Pharmaceuticals	£761.50M	0.00	-£27.90M	-£0.25	N/A

Do analysts prefer GNS or DPH?

Genus currently has a consensus price target of GBX 2,150, suggesting a potential upside of 13.76%. Given Genus' stronger consensus rating and higher possible upside, equities research analysts plainly believe Genus is more favorable than Dechra Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genus	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Dechra Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Does the media refer more to GNS or DPH?

In the previous week, Genus had 1 more articles in the media than Dechra Pharmaceuticals. MarketBeat recorded 1 mentions for Genus and 0 mentions for Dechra Pharmaceuticals. Genus' average media sentiment score of 1.11 beat Dechra Pharmaceuticals' score of 0.00 indicating that Genus is being referred to more favorably in the media.

Company	Overall Sentiment
Genus	Positive
Dechra Pharmaceuticals	Neutral

Do insiders and institutionals hold more shares of GNS or DPH?

77.8% of Genus shares are owned by institutional investors. Comparatively, 105.5% of Dechra Pharmaceuticals shares are owned by institutional investors. 0.8% of Genus shares are owned by insiders. Comparatively, 9.3% of Dechra Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Is GNS or DPH more profitable?

Genus has a net margin of 1.18% compared to Dechra Pharmaceuticals' net margin of -3.66%. Genus' return on equity of 1.41% beat Dechra Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genus	1.18%	1.41%	3.31%
Dechra Pharmaceuticals	-3.66%	-3.92%	0.75%

Which has more volatility and risk, GNS or DPH?

Genus has a beta of 0.37, indicating that its stock price is 63% less volatile than the S&P 500. Comparatively, Dechra Pharmaceuticals has a beta of 0.78, indicating that its stock price is 22% less volatile than the S&P 500.

Is GNS or DPH a better dividend stock?

Genus pays an annual dividend of GBX 32 per share and has a dividend yield of 1.7%. Dechra Pharmaceuticals pays an annual dividend of GBX 45 per share. Genus pays out 265.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Dechra Pharmaceuticals pays out -18,000.0% of its earnings in the form of a dividend.

Summary

Genus beats Dechra Pharmaceuticals on 14 of the 19 factors compared between the two stocks.